Trial Profile
Long term changes in bone mineral density and fracture risk in patients receiving androgen deprivation therapy [bicalutamide, goserelin] for advanced prostate cancer, with stratification of treatment based on presenting values
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 12 Oct 2007 New trial record.